Bessemer Group’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Bessemer Group’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-160	Closed	-$6K	–	2077
2022 Q1	$6K	Hold	160	–	–	﹤0.01%	1495
2021 Q4	$5K	Hold	160	–	–	﹤0.01%	1611
2021 Q3	$4K	Hold	160	–	–	﹤0.01%	1561
2021 Q2	$6K	Hold	160	–	–	﹤0.01%	1420
2021 Q1	$7K	Sell	160 -340	-68%	-$15.6K	﹤0.01%	1364
2020 Q4	$22K	Sell	500 -150	-23%	-$7.39K	﹤0.01%	1164
2020 Q3	$36K	Sell	650 -350	-35%	-$22.2K	﹤0.01%	971
2020 Q2	$63K	Buy	+1,000	New	+$68.6K	﹤0.01%	1316
2017 Q4	–	Sell	-50,009	Closed	-$1.55M	–	1855
2017 Q3	$1.55M	Hold	50,009	–	–	0.01%	520
2017 Q2	$1.37M	Buy	+50,009	New	+$1.49M	0.01%	575
2017 Q1	–	Sell	-23,160	Closed	-$335K	–	1953
2016 Q4	$335K	Buy	+23,160	New	+$407K	﹤0.01%	981

Other funds holding GBT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Bessemer Group's GBT Position: Q2 2022 in Review

Bessemer Group sold out of Global Blood Therapeutics, Inc. (GBT) in Q2 2022, closing a stake of 160 shares — an estimated $6K sold.

Bessemer Group first reported a position in GBT in Q4 2016 and held it in 11 quarters. The position peaked at $1.55M in Q3 2017. 195 funds tracked by Wall St. Rank hold GBT as of Q2 2022.

Bessemer Group reported no remaining Global Blood Therapeutics, Inc. position as of Q2 2022 after selling out during the quarter.
Bessemer Group sold 160 Global Blood Therapeutics, Inc. shares in Q2 2022, an estimated $6K.
Bessemer Group first reported a position in Global Blood Therapeutics, Inc. in Q4 2016 and held it in 11 quarters.
Bessemer Group's Global Blood Therapeutics, Inc. position peaked at $1.55M in Q3 2017.
195 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q2 2022.

Based on Bessemer Group's 13F filing for Q2 2022, filed 10 Aug 2022.